RedChip Client: Osteologix, Inc. (OLGX.OB) Announces Q1 2007 Research Update
Osteologix has completed its enrollment in the “Strong Study”, completed its phase II clinical trial, introduced a new and improved dosage form of Strontium, and treated osteoporosis in several European countries. The results from phase II should be received in the next seven month. If the results meet the target endpoint, the stock is expected to see substantial appreciation. The analyst stated, “At current price levels, OLGX deserves a Buy rating.” The analyst concluded, “We initiated coverage of Osteologix in January with a Speculative Buy rating and a 12 month price target of $3.88. Our target price is based on…